Pharmacovigilance, the continuous monitoring of the safety of medicines after they enter the market has moved from being a back-office function to a core regulatory and commercial discipline. In Iraq, pharmacovigilance has developed into a structured program with defined obligations for manufacturers, importers, and scientific offices, anchored in the Public Health Law No. 89 of 1981, pharmacovigilance instructions issued by the Ministry of Health and the IDCD, and internationally recognized guidelines that Iraq has progressively adopted. Companies that treat pharmacovigilance as an afterthought are increasingly exposed; companies that build it into their commercial operations from the start tend to avoid the more painful regulatory and reputational consequences.
The clinical case for robust pharmacovigilance is straightforward. Clinical trials provide important pre-marketing safety data, but they cannot identify all risks: rare adverse events appear only with widespread real-world use, long-term effects may emerge over years, special populations not studied in trials may experience different effects, and drug-drug interactions may be discovered after launch. The regulatory case is equally straightforward: the Iraqi authorities expect manufacturers and their local representatives to be vigilant about these risks, to report them appropriately, and to take action when the risk-benefit balance of a product changes.
Who Bears the Obligations?
Primary responsibility rests with the marketing authorization holder typically the manufacturer, local or foreign and with the scientific office or licensed importer that represents the manufacturer in Iraq. Healthcare professionals are encouraged, and in some cases required, to report adverse events through national systems, but the commercial pharmacovigilance burden falls on the company side of the equation. Foreign manufacturers commonly rely on their scientific office to maintain the day-to-day pharmacovigilance function in Iraq, but the legal responsibility cannot be wholly outsourced, the manufacturer remains accountable for the system as a whole.
Reporting Adverse Events
Adverse event reporting follows defined timelines. Fatal or life-threatening reactions are typically reported within seven days; serious non-fatal reactions within fifteen days; non-serious reactions in periodic safety updates. Reports must include patient demographics, suspect product and dose, reaction description, outcome, and reporter information. The reporting clock starts from the moment the company first becomes aware of the event, not from later confirmation, and this point is sometimes a source of misunderstanding within commercial organizations.
Pharmacovigilance Systems
Beyond individual case reporting, manufacturers and importers must maintain pharmacovigilance systems capable of receiving and evaluating safety information, documenting and reporting events, and detecting signals from various sources. The system typically includes a qualified person responsible for pharmacovigilance (functionally equivalent to a QPPV in other jurisdictions), standard operating procedures, staff training programs, and access to multiple sources of safety information, spontaneous reports, scientific literature, regulatory communications, and product complaints among them. Audits of pharmacovigilance systems are increasingly part of routine regulatory inspections, and inadequate systems are a common finding.
Periodic Reports and Risk Management Plans
Periodic Safety Update Reports, or their equivalent, are required at intervals defined by the Ministry of Health and summarize worldwide safety experience with the product, new reports received, signal evaluations, and assessment of whether label changes or risk management measures are warranted. Risk Management Plans may be required for new chemical entities, biologics, products with known significant risks, and products approved on the basis of limited data. An RMP describes the safety specification of the product, the routine and additional pharmacovigilance activities that will be conducted, and the risk minimization measures, restricted distribution, educational materials, special monitoring, that will be put in place.
Signal Management and Recalls
Signal management is the structured process for identifying, validating, and assessing safety signals, information suggesting a potential causal association between a drug and an adverse event. Depending on the nature and strength of the signal, response can range from label changes, additional safety studies, and risk communications through to restricted use and, in the most serious cases, market withdrawal. Recalls are part of the pharmacovigilance and quality system and may be initiated by the manufacturer, the importer, or the Ministry of Health, often in coordination with foreign regulators. Recalls are classified by the severity of the risk: Class I for serious risk of death or serious injury, Class II for temporary or medically reversible consequences, and Class III for events unlikely to cause adverse health consequences. Companies operating in Iraq need a documented recall procedure, communication channels to wholesalers, pharmacies, and hospitals, and the ability to verify effectiveness of the recall.
Risk Communication
Risk communication is an important pharmacovigilance output. Safety-related changes to the label, Dear Healthcare Professional letters, and patient information updates must be prepared and disseminated promptly when warranted, in many cases subject to regulatory review and approval. The content of these communications must align with the approved product information and reflect Iraqi context; simple translation of communications prepared for other markets is rarely adequate.
Consequences of Non-Compliance
Consequences of pharmacovigilance failures range from administrative warnings and fines through to suspension of the marketing authorization and, in serious cases, revocation. Criminal liability may attach in cases where willful concealment of safety information has contributed to patient harm. The reputational consequences can be significant, particularly for manufacturers operating in multiple markets where regulators communicate with one another. A pharmacovigilance failure detected in Iraq can prompt parallel scrutiny in other markets where the same product is sold.
How We Can Help
Etihad Law Firm advises pharmaceutical manufacturers, scientific offices, and importers on the design, implementation, and audit of pharmacovigilance systems in Iraq. We assist in drafting standard operating procedures, training programs, recall procedures, and Risk Management Plans, and we represent clients in regulatory inspections, enforcement actions, and product liability matters arising from post-market safety issues.